These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24316184)

  • 21. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria.
    Bijur GN; Jope RS
    Neuroreport; 2003 Dec; 14(18):2415-9. PubMed ID: 14663202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors.
    Chen L; Zhou W; Chen PC; Gaisina I; Yang S; Li X
    Mol Pharmacol; 2011 Jun; 79(6):974-86. PubMed ID: 21372171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoskeleton involvement in lithium-induced SH-SY5Y neuritogenesis and the role of glycogen synthase kinase 3β.
    Nciri R; Boujbiha MA; Jbahi S; Allagui MS; Elfeki A; Vincent C; Croute F
    Aging Clin Exp Res; 2015 Jun; 27(3):255-63. PubMed ID: 25409859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cocaine-induced hyperactivity and sensitization are dependent on GSK3.
    Miller JS; Tallarida RJ; Unterwald EM
    Neuropharmacology; 2009 Jun; 56(8):1116-23. PubMed ID: 19328817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of glycogen synthase kinase-3 reduces extension of the axonal leading process by destabilizing microtubules in cerebellar granule neurons.
    Inami Y; Omura M; Kubota K; Konishi Y
    Brain Res; 2018 Jul; 1690():51-60. PubMed ID: 29653082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GSK3 alpha and GSK3 beta are necessary for axon formation.
    Garrido JJ; Simón D; Varea O; Wandosell F
    FEBS Lett; 2007 Apr; 581(8):1579-86. PubMed ID: 17391670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
    Mangangcha IR; Brojen Singh RK; Lebeche D; Ali S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7868-7884. PubMed ID: 33769184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GSK3 beta N-terminus binding to p53 promotes its acetylation.
    Eom TY; Jope RS
    Mol Cancer; 2009 Mar; 8():14. PubMed ID: 19265551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
    Coats JT; Tauro S; Sutherland C
    Cell Commun Signal; 2023 Jun; 21(1):131. PubMed ID: 37316860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycogen synthase kinase 3 signaling in neural regeneration in vivo.
    Zhang J; Yang SG; Zhou FQ
    J Mol Cell Biol; 2024 Apr; 15(12):. PubMed ID: 38059848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
    Qu L; Li S; Ji L; Luo S; Ding M; Yin F; Wang C; Luo H; Lu D; Liu X; Peng W; Kong L; Wang X
    Eur J Med Chem; 2021 Dec; 226():113889. PubMed ID: 34649182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases.
    Wang L; Li J; Di LJ
    Med Res Rev; 2022 Mar; 42(2):946-982. PubMed ID: 34729791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor.
    Phyu SM; Tseng CC; Smith TAD
    MAGMA; 2019 Apr; 32(2):227-235. PubMed ID: 30446846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of endothelial cell morphogenesis by the protein kinase D (PKD)/glycogen synthase kinase 3 (GSK3)β pathway.
    Shin S; Wolgamott L; Yoon SO
    Am J Physiol Cell Physiol; 2012 Oct; 303(7):C743-56. PubMed ID: 22855295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underlying mechanisms of glucocorticoid-induced β-cell death and dysfunction: a new role for glycogen synthase kinase 3.
    Delangre E; Liu J; Tolu S; Maouche K; Armanet M; Cattan P; Pommier G; Bailbé D; Movassat J
    Cell Death Dis; 2021 Dec; 12(12):1136. PubMed ID: 34876563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review.
    Glibo M; Serman A; Karin-Kujundzic V; Bekavac Vlatkovic I; Miskovic B; Vranic S; Serman L
    Bosn J Basic Med Sci; 2021 Feb; 21(1):5-18. PubMed ID: 32767962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lactate's effect on human neuroblastoma cell bioenergetic fluxes.
    E L; Swerdlow RH
    Biochem Pharmacol; 2016 Jan; 99():88-100. PubMed ID: 26592660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of GSK3 in metabolic pathway perturbations in cancer.
    Papadopoli D; Pollak M; Topisirovic I
    Biochim Biophys Acta Mol Cell Res; 2021 Jul; 1868(8):119059. PubMed ID: 33989699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GSK3 signalling in neural development.
    Hur EM; Zhou FQ
    Nat Rev Neurosci; 2010 Aug; 11(8):539-51. PubMed ID: 20648061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced glycolysis and GSK3 inactivation promote brain metabolic adaptations following neuronal mitochondrial stress.
    Garcia S; Saldana-Caboverde A; Anwar M; Raval AP; Nissanka N; Pinto M; Moraes CT; Diaz F
    Hum Mol Genet; 2022 Mar; 31(5):692-704. PubMed ID: 34559217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.